{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:41:37Z","timestamp":1787038897474,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.xphs.2018.10.063","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T11:30:42Z","timestamp":1542454242000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs"],"prefix":"10.1016","volume":"108","author":[{"given":"Kai","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2018.10.063_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/asheducation-2014.1.151","article-title":"Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era","volume":"1","author":"Graf","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.xphs.2018.10.063_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.xphs.2018.10.063_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.2012.48.4.1788435","article-title":"Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin\u2019s lymphoma","volume":"48","author":"Haddley","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.xphs.2018.10.063_bib4","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2018.10.063_bib5","first-page":"103","article-title":"Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer","volume":"6","author":"Oostra","year":"2014","journal-title":"Breast Cancer"},{"key":"10.1016\/j.xphs.2018.10.063_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-014-0201-0","article-title":"Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2018.10.063_bib7","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.xphs.2018.10.063_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xphs.2018.10.063_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-13-0541","article-title":"Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer","volume":"20","author":"Krop","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xphs.2018.10.063_bib10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2018.10.063_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.seminoncol.2014.08.001","article-title":"The next generation of antibody drug conjugates","volume":"41","author":"Mack","year":"2014","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.xphs.2018.10.063_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.063_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.063_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.063_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.063_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.coph.2005.04.008","article-title":"Arming antibodies for cancer therapy","volume":"5","author":"Polakis","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.xphs.2018.10.063_bib17","first-page":"315","article-title":"The intramolecular Michael reaction","volume":"47","author":"Little","year":"1995","journal-title":"Org React"},{"issue":"11","key":"10.1016\/j.xphs.2018.10.063_bib18","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2018.10.063_bib19","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1007\/s10875-016-0265-6","article-title":"Current status: site-specific antibody drug conjugates","volume":"36","author":"Schumacher","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.063_bib20","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.3390\/biomedicines5040064","article-title":"Site-specific antibody conjugation for ADC and beyond","volume":"5","author":"Zhou","year":"2017","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.063_bib21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41467-017-01257-1","article-title":"Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates","volume":"8","author":"Nanna","year":"2017","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.xphs.2018.10.063_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.063_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation site modulates the in\u00a0vivo stability and therapeutic activity of antibody-drug conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.063_bib24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2018.10.063_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.063_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/bc7004329","article-title":"Contribution of linker stability to the activities of anticancer immunoconjugates","volume":"19","author":"Alley","year":"2008","journal-title":"Bioconjug Chem"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.063_bib27","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1021\/bc200148v","article-title":"Tunable degradation of maleimide-thiol adducts in reducing environments","volume":"22","author":"Baldwin","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"33","key":"10.1016\/j.xphs.2018.10.063_bib28","doi-asserted-by":"crossref","first-page":"22549","DOI":"10.1016\/S0021-9258(18)54607-X","article-title":"Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides","volume":"266","author":"Tyler-Cross","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"4849","key":"10.1016\/j.xphs.2018.10.063_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.3353715","article-title":"Tertiary structure is a principal determinant to protein deamidation","volume":"240","author":"Kossiakoff","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.063_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","article-title":"Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates","volume":"20","author":"Strop","year":"2013","journal-title":"Chem Biol"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.063_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/bc5005747","article-title":"Effect of attachment site on stability of cleavable antibody drug conjugates","volume":"26","author":"Dorywalska","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"17","key":"10.1016\/j.xphs.2018.10.063_bib32","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1021\/ac301568f","article-title":"Profiling antibody drug conjugate positional isomers: a system-of-equations approach","volume":"84","author":"Le","year":"2012","journal-title":"Anal Chem"},{"issue":"12","key":"10.1016\/j.xphs.2018.10.063_bib33","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1021\/ac100575n","article-title":"Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis","volume":"82","author":"Liu","year":"2010","journal-title":"Anal Chem"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.063_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1021\/jp808597v","article-title":"Deamidation of asparagine residues: direct hydrolysis versus succinimide-mediated deamidation mechanisms","volume":"113","author":"Catak","year":"2009","journal-title":"J\u00a0Phys Chem A"},{"issue":"Pt B","key":"10.1016\/j.xphs.2018.10.063_bib35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2018.10.063_bib36","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1248\/cpb.25.2739","article-title":"Hydrolysis of N substituted maleimides: stability of fluorescence thiol reagents in aqueous media","volume":"25","author":"Machida","year":"1977","journal-title":"Chem Pharm Bull"},{"issue":"10","key":"10.1016\/j.xphs.2018.10.063_bib37","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.063_bib38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/bc400245v","article-title":"A\u00a0new reagent for stable thiol-specific conjugation","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjug Chem"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491830707X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491830707X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:22:55Z","timestamp":1758360175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491830707X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S002235491830707X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.063","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}